in111 ll2 igg
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 1997 (NCT00004086)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD22INHIBITOR
CD22 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- in111 ll2 igg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004084 | Phase 1/Phase 2 (Phase 2) | Apr 1, 1998 | Garden State Cancer Center, National Cancer Institute (NCI) |
| NCT00004086 | Phase 1 | Jun 1, 1997 | Garden State Cancer Center |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Garden State Cancer Center | Academic/Hospital | 2 | 2 | 2 | 1997 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1998 |
2 organizations
Page 1 / 1